Danish Cancer Institute posted on LinkedIn about recent paper by Loulieta Nazerai et al., titled “Thiopurine therapy enhances immune checkpoint inhibitor efficacy in low-mutational burden melanoma: A promising anticancer approach” published on PNAS.
Authors: Loulieta Nazerai, Christina Tsiavou, Lina Vardouli, Kjeld Schmiegelow, and Daniela De Zio
“‘I hope my research will improve the options for patients who don’t have many options at the moment.’
Meet Loulieta Nazerai, Postdoc in the Melanoma Research Team led by Daniela De Zio.
Loulieta specialises in cancer immunotherapy, and recently her research led to an important discovery that could change the treatment landscape for patients with resistant melanoma.”
Video attached to the post.